# 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

> **NCT04019873** · — · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 774 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Lamivudine (3TC)
- **DRUG:** Rilpivirine (RPV)

## Key facts

- **NCT ID:** NCT04019873
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-18
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-12-05
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019873, "'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04019873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*